TransCode appoints Tungsten Advisors to explore TTX-MC138 licensing and sale options as its ctDNA-positive colorectal cancer trial advances.
Natera reports 91% two-year event-free survival in persistently ctDNA-negative VOLGA patients, strengthening MRD research in bladder cancer.
Natera Inc. and Medica Scientia Innovation Research (MEDSIR) have announced a collaborative effort on the MiRaDoR study, a multicenter, phase II clinical trial focused on hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Sponsored by MEDSIR and funded by F. Hoffmann-La Roche Ltd., the trial uses Natera’s Signatera assay to guide therapy decisions based on circulating tumor